Porphyria Therapies

About Recordati

Founded in 1926 by Giovanni Recordati, this Milan-based pharmaceutical group has evolved from a family pharmacy into a global pharmaceutical force with operations in ~150 countries. The company focuses on both common conditions affecting large populations and rare diseases with limited treatment options, operating through integrated R&D, manufacturing, and commercial capabilities. With a market valuation of approximately €10.5 billion and strong presence in Europe, the company continues expanding its specialty and rare disease portfolio while maintaining its commitment to 'unlocking the full potential of life.'

Therapeutic Areas